Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Braz. j. med. biol. res ; 54(2): e10099, 2021. tab
Article in English | LILACS, ColecionaSUS | ID: biblio-1142582

ABSTRACT

The objective of this study was to analyze the infection rate and drug resistance of Ureaplasma urealyticum (UU) and Mycoplasma hominis (MH) in the genitourinary tract of Chinese patients. From December 2018 to June 2019, vaginal secretion or urinary secretion of outpatients in our hospital were selected for culture and drug sensitivity analysis of Ureaplasma urealyticum and Mycoplasma hominis. In 4082 Chinese samples, 1567 Mycoplasma were detected, a detection rate of 38.39%, among which 1366 cases were UU single positive, accounting for 33.47%, 15 cases were MH single positive, accounting for 0.36%, 186 cases were UU and MH mixed positive, accounting for 4.56%. The most affected age groups were 21-30 years and 31-40 years, accounting for 19.09 and 15.05%, respectively. The results of drug sensitivity showed that doxycycline, minocycline, josamycin, clarithromycin, and roxithromycin were more sensitive to mycoplasma infection. The distribution of Ureaplasma urealyticum and Mycoplasma hominis in the human genitourinary system and their sensitivity to antibiotics is different for sex and age groups.


Subject(s)
Humans , Male , Female , Adult , Young Adult , Ureaplasma urealyticum/drug effects , Ureaplasma Infections/microbiology , Mycoplasma hominis/drug effects , Microbial Sensitivity Tests , China , Ureaplasma urealyticum/isolation & purification , Mycoplasma hominis/isolation & purification , Asian Continental Ancestry Group , Anti-Bacterial Agents/pharmacology
2.
Yonsei Medical Journal ; : 1271-1275, 2016.
Article in English | WPRIM | ID: wpr-79764

ABSTRACT

Mycoplasma hominis (M. hominis) and Ureaplasma urealyticum (U. urealyticum) are important opportunistic pathogens that cause urogenital infections and complicate pregnancy. The aim of this study was to investigate the prevalence, effects on pregnancy outcomes, and antimicrobial susceptibilities of M. hominis and U. urealyticum. We tested vaginal swabs obtained from 1035 pregnant women for the presence of genital mycoplasmas between June 2009 and May 2014. The laboratory and clinical aspects of genital mycoplasmas infection were reviewed retrospectively, and the identification and antimicrobial susceptibility of genital mycoplasmas were determined using the Mycoplasma IST-2 kit. A total of 571 instances of M. hominis and/or U. urealyticum were detected. Of them, M. hominis was detected in two specimens, whereas U. urealyticum was detected in 472 specimens. The remaining 97 specimens were positive for both M. hominis and U. urealyticum. Preterm deliveries were frequently observed in cases of mixed infection of M. hominis and U. urealyticum, and instances of preterm premature rupture of membrane were often found in cases of U. urealyticum. The rates of non-susceptible isolates to erythromycin, empirical agents for pregnant women, showed increasing trends. In conclusion, the prevalence of M. hominis and/or U. urealyticum infections in pregnant women is high, and the resistance rate of antimicrobial agents tends to increase. Therefore, to maintain a safe pregnancy, it is important to identify the isolates and use appropriate empirical antibiotics immediately.


Subject(s)
Adolescent , Adult , Anti-Bacterial Agents/pharmacology , Female , Humans , Infant, Newborn , Microbial Sensitivity Tests , Middle Aged , Mycoplasma Infections/drug therapy , Mycoplasma hominis/drug effects , Pregnancy , Pregnancy Complications, Infectious/drug therapy , Pregnancy Outcome , Prevalence , Retrospective Studies , Ureaplasma Infections/drug therapy , Ureaplasma urealyticum/drug effects , Young Adult
3.
Braz. j. microbiol ; 45(1): 239-242, 2014. tab
Article in English | LILACS | ID: lil-709485

ABSTRACT

To evaluate the molecular mechanism of fluoroquinolones resistance in Mycoplasma hominis (MH) clinical strains isolated from urogenital specimens. 15 MH clinical isolates with different phenotypes of resistance to fluoroquinolones antibiotics were screened for mutations in the quinolone resistance-determining regions (QRDRs) of DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE) in comparison with the reference strain PG21, which is susceptible to fluoroquinolones antibiotics. 15 MH isolates with three kinds of quinolone resistance phenotypes were obtained. Thirteen out of these quinolone-resistant isolates were found to carry nucleotide substitutions in either gyrA or parC. There were no alterations in gyrB and no mutations were found in the isolates with a phenotype of resistance to Ofloxacin (OFX), intermediate resistant to Levofloxacin (LVX) and Sparfloxacin (SFX), and those susceptible to all three tested antibiotics. The molecular mechanism of fluoroquinolone resistance in clinical isolates of MH was reported in this study. The single amino acid mutation in ParC of MH may relate to the resistance to OFX and LVX and the high-level resistance to fluoroquinolones for MH is likely associated with mutations in both DNA gyrase and the ParC subunit of topoisomerase IV.


Subject(s)
Humans , Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Fluoroquinolones/pharmacology , Mutation, Missense , Mycoplasma Infections/microbiology , Mycoplasma hominis/drug effects , Reproductive Tract Infections/microbiology , DNA Gyrase/genetics , DNA Topoisomerase IV/genetics , Mycoplasma hominis/genetics , Mycoplasma hominis/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL